Using saliva to predict lung complications in premature infants
Official title: Salivary miRNAs as Prognostic Markers of Pulmonary Hypertension Associated with Bronchopulmonary Dysplasia in Extremely Low Gestational Age Infants
Funded at Pennsylvania State Univ Hershey Med Ctr · NIH-10895439 · Data updated 2026-11-12
This study is looking at how tiny molecules in saliva might help doctors predict lung problems in premature babies, so they can catch issues early and provide better care.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State Univ Hershey Med Ctr NIH-funded |
| Lab location | 1 site (Hershey, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $173,619 |
| NIH project number | 5K23HD109727-02 |
| Project ID | NIH-10895439 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are extremely low gestational age infants who are at risk for developing bronchopulmonary dysplasia and pulmonary hypertension.
✕Less likely to help
Patients who are not extremely low gestational age infants or those who do not have bronchopulmonary dysplasia may not benefit from this research.
What this research studies
This research investigates the use of salivary microRNAs as potential markers to predict pulmonary hypertension associated with bronchopulmonary dysplasia in extremely low gestational age infants. By analyzing saliva samples, the study aims to identify non-invasive biomarkers that can help healthcare providers assess the risk of developing severe lung complications in these vulnerable infants. The approach focuses on early detection, which could lead to timely interventions and improved management of affected infants. The research will involve collecting saliva samples and correlating the findings with clinical outcomes.
Why it matters
Potential benefit: If successful, this research could lead to earlier identification and better management of lung complications in premature infants, potentially reducing morbidity and mortality.
How similar studies have gone: Previous research has shown promise in using biomarkers for predicting outcomes in similar patient populations, indicating that this approach may be viable.
Where this research is happening
-
Pennsylvania State Univ Hershey Med Ctr
Hershey, United States Active
Researchers
- Principal investigator: Siddaiah, Roopa — Pennsylvania State Univ Hershey Med Ctr
- Study coordinator: Siddaiah, Roopa
Related research
Other NIH-funded projects on the same topics.
-
Regulatory T Cells and Lung Disease-Related High Blood Pressure in Adults
This project studies how a type of immune cell called regulatory T cells may influence inflammation and blood vessel changes in lung disease, with potential relevance to adults who have vascular issues in their lungs.
-
L-Citrulline for BPD-related Pulmonary Hypertension in Preterm Babies
A first-in-human study will test safe and effective doses of L-citrulline given by mouth to stability-preterm infants at risk for lung blood pressure problems.
-
Metabolic clues to BPD-related pulmonary hypertension in babies and teens and adults
This grant aims to understand why a serious lung condition in preterm babies can lead to high blood pressure in the lungs, with the goal of finding new treatments.
-
New treatments for lung problems in premature infants
This study is looking for new ways to help premature babies who have bronchopulmonary dysplasia and high blood pressure in their lungs, with the goal of making them healthier and reducing serious health risks.
-
Understanding how metabolic processes affect lung disease in premature infants
This study is looking at how certain changes in the lungs of premature babies with bronchopulmonary dysplasia can lead to high blood pressure in the lungs, and it hopes to find new ways to help treat or prevent this condition.
-
Understanding how CD4 T cells fuel schistosomiasis-related lung disease
A study explores how specific immune cells and inflammatory signals in schistosomiasis may contribute to pulmonary hypertension in people affected by the disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.